Literature DB >> 29417338

Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment.

Naveen Kumar1, Peeyush Prasad1, Eshna Jash1, Megha Saini2, Amjad Husain3, Aaron Goldman4,5,6, Seema Sehrawat7,8.   

Abstract

Cancer remains a global health problem and approximately 1.7 million new cancer cases are diagnosed every year worldwide. Although diverse molecules are currently being explored as targets for cancer therapy the tumor treatment and therapy is highly tricky. Secondary messengers are important for hormone-mediated signaling pathway. Cyclic AMP (cAMP), a secondary messenger responsible for various physiological processes regulates cell metabolism by activating Protein kinase A (PKA) and by targeting exchange protein directly activated by cAMP (EPAC). EPAC is present in two isoforms EPAC1 and EPAC2, which exhibit different tissue distribution and is involved in GDP/GTP exchange along with activating Rap1- and Rap2-mediated signaling pathways. EPAC is also known for its dual role in cancer as pro- and anti-proliferative in addition to metastasis. Results after perturbing EPAC activity suggests its involvement in cancer cell migration, proliferation, and cytoskeleton remodeling which makes it a potential therapeutic target for cancer treatments.

Entities:  

Keywords:  Brain cancer; Breast cancer therapy; EPAC; Leukemia; Melanoma; Metastasis; Ovarian cancer; cAMP signaling

Mesh:

Substances:

Year:  2018        PMID: 29417338     DOI: 10.1007/s11010-018-3294-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  121 in total

1.  Epac1-Rap1 signaling regulates monocyte adhesion and chemotaxis.

Authors:  Magdalena J Lorenowicz; Janine van Gils; Martin de Boer; Peter L Hordijk; Mar Fernandez-Borja
Journal:  J Leukoc Biol       Date:  2006-08-29       Impact factor: 4.962

2.  Dynamically driven ligand selectivity in cyclic nucleotide binding domains.

Authors:  Rahul Das; Somenath Chowdhury; Mohammad T Mazhab-Jafari; Soumita Sildas; Rajeevan Selvaratnam; Giuseppe Melacini
Journal:  J Biol Chem       Date:  2009-04-29       Impact factor: 5.157

3.  5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP.

Authors:  Haijun Chen; Tamara Tsalkova; Fang C Mei; Yaohua Hu; Xiaodong Cheng; Jia Zhou
Journal:  Bioorg Med Chem Lett       Date:  2012-04-26       Impact factor: 2.823

4.  Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

Authors:  S S Pullamsetti; G A Banat; A Schmall; M Szibor; D Pomagruk; J Hänze; E Kolosionek; J Wilhelm; T Braun; F Grimminger; W Seeger; R T Schermuly; R Savai
Journal:  Oncogene       Date:  2012-04-23       Impact factor: 9.867

5.  Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization.

Authors:  W C Colley; T C Sung; R Roll; J Jenco; S M Hammond; Y Altshuller; D Bar-Sagi; A J Morris; M A Frohman
Journal:  Curr Biol       Date:  1997-03-01       Impact factor: 10.834

6.  cAMP signalling decreases p300 protein levels by promoting its ubiquitin/proteasome dependent degradation via Epac and p38 MAPK in lung cancer cells.

Authors:  Min-Jae Jeong; Eui-Jun Kim; Eun-Ah Cho; Sang-Kyu Ye; Gyeong Hoon Kang; Yong-Sung Juhnn
Journal:  FEBS Lett       Date:  2013-03-20       Impact factor: 4.124

7.  The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals.

Authors:  Utako Yokoyama; Hemal H Patel; N Chin Lai; Nakon Aroonsakool; David M Roth; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-23       Impact factor: 11.205

8.  Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells.

Authors:  Jeong Ah Lim; Yong-Sung Juhnn
Journal:  Exp Mol Med       Date:  2016-01-15       Impact factor: 8.718

9.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

10.  Differential and synergistic actions of nerve growth factor and cyclic AMP in PC12 cells.

Authors:  P W Gunning; G E Landreth; M A Bothwell; E M Shooter
Journal:  J Cell Biol       Date:  1981-05       Impact factor: 10.539

View more
  10 in total

Review 1.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

2.  Phospho-substrate profiling of Epac-dependent protein kinase C activity.

Authors:  Diana J Goode; Derek C Molliver
Journal:  Mol Cell Biochem       Date:  2019-02-09       Impact factor: 3.396

3.  Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy.

Authors:  Naveen Kumar; Masoom Raza; Seema Sehrawat
Journal:  Mol Cell Biochem       Date:  2021-07-29       Impact factor: 3.396

4.  Overexpression of EPAC2 reduces the invasion of glioma cells via MMP-2.

Authors:  Ming Jiang; Yan Zhuang; Wang-Cun Zu; Lei Jiao; Seidu A Richard; Shiming Zhang
Journal:  Oncol Lett       Date:  2019-03-29       Impact factor: 2.967

5.  A Genetic Screen for Human Genes Suppressing FUS Induced Toxicity in Yeast.

Authors:  Elliott Hayden; Shuzhen Chen; Abagail Chumley; Chenyi Xia; Quan Zhong; Shulin Ju
Journal:  G3 (Bethesda)       Date:  2020-06-01       Impact factor: 3.154

6.  Origin and Isoform Specific Functions of Exchange Proteins Directly Activated by cAMP: A Phylogenetic Analysis.

Authors:  Zhuofu Ni; Xiaodong Cheng
Journal:  Cells       Date:  2021-10-14       Impact factor: 6.600

Review 7.  Epac: A Promising Therapeutic Target for Vascular Diseases: A Review.

Authors:  Yunfeng Pan; Jia Liu; Jiahui Ren; Yun Luo; Xiaobo Sun
Journal:  Front Pharmacol       Date:  2022-07-14       Impact factor: 5.988

8.  Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me2/3 Demethylases GSKJ4 Inhibitor via Protein Kinase A.

Authors:  Michela Illiano; Mariarosaria Conte; Luigi Sapio; Angela Nebbioso; Annamaria Spina; Lucia Altucci; Silvio Naviglio
Journal:  Front Pharmacol       Date:  2018-07-20       Impact factor: 5.810

9.  Identification of Key Genes and Pathways Associated with RUNX1 Mutations in Acute Myeloid Leukemia Using Bioinformatics Analysis.

Authors:  Fangxiao Zhu; Rui Huang; Jing Li; Xiwen Liao; Yumei Huang; Yongrong Lai
Journal:  Med Sci Monit       Date:  2018-10-05

Review 10.  Role of EPAC1 Signalosomes in Cell Fate: Friends or Foes?

Authors:  Karina Formoso; Frank Lezoualc'h; Jeanne Mialet-Perez
Journal:  Cells       Date:  2020-08-25       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.